OKYO Pharma Limited
NASDAQ:OKYO
2.535 (USD) • At close July 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.008 | 0.004 | 0.002 | 0.013 | 0.006 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.077 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.008 | -0.004 | -0.002 | -0.013 | -0.006 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 0.008 | 6.338 | 1.61 | 0.348 | 0.517 | 3.044 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0.573 | 0.363 | 1.05 | 1.744 | 4.607 | 4.671 | 0 | 0.832 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.002 | 0.005 | 0.063 | 0.073 |
| SG&A
| 7.447 | 6.746 | 4.928 | 2.974 | 0.995 | 1.854 | 0.573 | 0.363 | 1.05 | 1.744 | 4.607 | 4.671 | 5.159 | 0.834 | 0.005 | 0.063 | 0.073 |
| Other Expenses
| 0 | 0 | 0 | 0 | -0 | -0.016 | -0.012 | 0 | 0.049 | 0 | 0 | -0.066 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 0.008 | 13.187 | 6.218 | 3.366 | 1.513 | 4.539 | 0.986 | 0.363 | 1.098 | 1.751 | 4.774 | 4.672 | 5.414 | 1.703 | 1.017 | 2.226 | 3.165 |
| Operating Income
| -0.016 | -13.187 | -6.231 | -4.133 | -1.519 | -4.539 | -28.286 | -0.363 | -1.1 | -1.749 | -4.774 | -4.922 | -5.108 | -1.703 | -1.017 | 15.097 | -3.515 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.001 | -0.097 | 0.014 | 0.755 | -0.099 | -0.363 | -0.012 | 0.121 | 0.096 | 0.25 | -9.332 | 78.744 | -0.591 | 0 | 0 | 0 | 0 |
| Income Before Tax
| -16.803 | -13.284 | -6.218 | -3.379 | -1.618 | -4.902 | -28.267 | -0.242 | -1.01 | -1.494 | -13.927 | -4.84 | -5.7 | -1.617 | 12.673 | 14.335 | -2.975 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.012 | -0.787 | -0.025 | -0.076 | 0 | 0 | 0 | -0.19 | 6.761 | 0.004 | 0 | -0.895 | 0 | 0 | 0 | 0 |
| Net Income
| -0.017 | -13.272 | -5.431 | -3.354 | -1.542 | -4.895 | -28.299 | -0.243 | -0.82 | -8.255 | -13.946 | -4.839 | -4.804 | -1.617 | 12.673 | 14.335 | -2.975 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.001 | -0.6 | -0.36 | -0.32 | -0.17 | -0.62 | -4.8 | -0.041 | -0.17 | -1.32 | -0.046 | -1.09 | -1.12 | -0.38 | 2.96 | 0.48 | -0.054 |
| EPS Diluted
| -0.001 | -0.6 | -0.36 | -0.32 | -0.17 | -0.62 | -4.8 | -0.041 | -0.14 | -1.32 | -0.046 | -1.09 | -1.12 | -0.38 | 2.96 | 0.48 | -0.054 |
| EBITDA
| -0.016 | -13.183 | -6.215 | -3.353 | -1.513 | -4.539 | 26.169 | -0.363 | -1.125 | -1.751 | -4.671 | -4.696 | -5.089 | -1.703 | 28.613 | 15.097 | -3.165 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |